EVAX (Evaxion AS) Other Current Receivables: $1.86 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVAX Evaxion AS EVAX
50 GF Score
Price $2.97
GF Value $3.34
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Evaxion AS Other Current Receivables?

Evaxion AS EVAX -1.33% 50 Other Current Receivables is $1.86 Mil as of Jun. 2026. GuruFocus rates EVAX with a GF Score™ of 50/100 and a GF Value™ of $3.34 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Evaxion AS's Other Current Receivables for the quarter that ended in Jun. 2026 was $1.86 Mil.

Evaxion AS's quarterly Other Current Receivables declined from Dec. 2025 ($1.05 Mil) to Mar. 2026 ($0.00 Mil) but then increased from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($1.86 Mil).

Evaxion AS's annual Other Current Receivables increased from Dec. 2023 ($1.08 Mil) to Dec. 2024 ($1.86 Mil) but then declined from Dec. 2024 ($1.86 Mil) to Dec. 2025 ($1.05 Mil).

Evaxion AS Other Current Receivables Related Terms

Evaxion AS Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Evaxion AS's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion AS Other Current Receivables Chart

Evaxion AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 1.90 1.31 1.08 1.86 1.05

Evaxion AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.43 0.00 1.05 0.00 1.86
EVAX
50GF Score
Evaxion AS EVAX
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evaxion AS Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $1.86 Mil mean?
Evaxion AS (EVAX) has a Other Current Receivables of $1.86 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Evaxion AS and its competitors.
Is Evaxion AS's Other Current Receivables too high?
Evaxion AS's current Other Current Receivables is $1.86 Mil. Overall, Evaxion AS has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's Other Current Receivables compare to DYAI and ATOS?
Evaxion AS's Other Current Receivables of $1.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Evaxion AS and its competitors. Evaxion AS's current Other Current Receivables is $1.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Based on GuruFocus' analysis, Evaxion AS (EVAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.34, compared to a current price of $2.97 — trading 11.1% below its estimated fair value. The current Other Current Receivables is $1.86 Mil. Evaxion AS's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Evaxion AS (EVAX), the current Other Current Receivables is $1.86 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evaxion AS (EVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Evaxion AS stock appears to be undervalued. The current stock price of $2.97 is trading 11.1% below its estimated GF Value™ of $3.34. GuruFocus considers Evaxion AS to be Modestly Undervalued.

Key valuation signals for EVAX:

  • Other Current Receivables: $1.86 Mil
  • GF Value™: $3.34 vs. price of $2.97 (11.1% below fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
50GF Score

Get the complete analysis for EVAX

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.97
Price
$3.34
GF Value